NCT07690189RecruitingPhase 1
Study of NTB-928 in R/R OC
A Phase 1 Multicenter, Open-Label, Dose-Escalation and Expansion Study of NTB-928, a FRα-Targeting Bispecific T Cell Engager, in Subjects With Relapsed/Refractory Ovarian Carcinoma
Source: ClinicalTrials.gov · Last updated 20 Aug 2026
Brief summary (registry, in English)
The goal of this clinical trial is to determine if NTB-928 can be given safely to adult females with ovarian cancer that has come back (relapsed) or stopped responding to treatment (refractory), how NTB-928 moves through the body, and how the immune system reacts to it. The study will also look for early signs of anti-cancer activity of NTB-928. The main questions the study aims to answer are: * What side effects do participants experience when receiving NTB-928, including side effects that limit how much of it can be safely given? * How is NTB-928 processed by the body at different dose levels? * Does the immune system react to NTB-928 during treatment? * What dose of NTB-928 can be given safely that shows early signs of activity against ovarian cancer?
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 90 (estimated)
- First submitted
- 2 Jul 2026
- Start date
- 29 Jun 2026
- Primary completion date
- 30 Jun 2028
- Lead sponsor
- TeneoSeven, Inc.
- Diseases
- Ovarian cancer
- NCT number
- NCT07690189
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 90
- From 29 Jun 2026 to the primary completion date, 30 Jun 2028
- 4 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Have received another investigational drug or certain cancer treatments within a recent period before starting this study
Other illness
- Have another active cancer that could interfere with assessment of this study treatment
Other
- Are pregnant or breastfeeding
Who the study is looking for
- Aged 18 years or older
- Have a confirmed diagnosis of ovarian cancer, including high-grade serous, high-grade endometrioid, low-grade serous, or clear cell ovarian cancer, or carcinosarcoma of the ovary. Patients with mucinous carcinoma are not eligible.
- Have relapsed or refractory ovarian cancer and have already received standard treatments known to provide benefit; participants are eligible if they have platinum-refractory, platinum-resistant, or platinum-sensitive ovarian cancer (with clearly documented ineligibility for further platinum chemotherapy).
- Are able to understand the study requirements and are willing to provide written informed consent
- Are willing to use effective birth control during the study and for a period after the last dose of study treatment, if of childbearing potential
Age in the registry: 18 years to - · Sex: Female · Does not accept healthy volunteers
Sites (4)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The University of Alabama Coordinator of this site? Confirm its status | Birmingham | United States | Recruiting |
| Start Ccbd, Llc Coordinator of this site? Confirm its status | Fort Worth | United States | Recruiting |
| START Northwell, LLC Coordinator of this site? Confirm its status | Lake Success | United States | Recruiting |
| University of Nebraska Medical Center Coordinator of this site? Confirm its status | Omaha | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.